Details:
This cooperation agreement designates CBL as the exclusive manufacturing partner for synthetic human relaxin-2 (GMP and non-GMP) and Relaxera as the exclusive sales executive partner for relaxin.
Lead Product(s): Relaxin-2 protein, human
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Peptide
Recipient: Relaxera Pharmazeutische
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 16, 2020